Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data

Objective: Ustekinumab is used in moderate-severe plaque psoriasis with inadequate response to anti- tumour necrosis factor α drugs. Recent studies support the need to assess real long-term data. The aim of this study was to evaluate the real long-term effectiveness and safety of ustekinuma...

Full description

Bibliographic Details
Main Authors: Manuel David Gil-Sierra, Esmeralda Ríos-Sánchez, María del Pilar Briceño-Casado
Format: Article
Language:English
Published: Grupo Aula Médica 2020-09-01
Series:Farmacia Hospitalaria
Subjects:
Online Access:http://www.aulamedica.es/fh/pdf/11420.pdf